Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Camus

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
Depression and Anxiety|January 31, 2020
Childhood maltreatment and clinical severity of treatment-resistant depression in a French cohort of outpatients (FACE-DR): One-year follow-upAntoine Yrondi, Bruno Aouizerate, Djamila Bennabi, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|April 29, 2023
Long-term benzodiazepine prescription in treatment-resistant depression: A national FACE-TRD prospective studyGuillaume Fond, Mélanie Faugere, Laurent Boyer, et al.
BMJ Open|July 28, 2022
Impact of a phone call with a medical student/general practitioner team on morbidity of chronic patients during the first French COVID-19 lockdown (COVIQuest): a cluster randomised trialClarisse Dibao-Dina, Julie Léger, Isabelle Ettori-Ajasse, et al.
Frontiers in Psychiatry|December 12, 2017
Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental)Antoine Yrondi, Djamila Bennabi, Emmanuel Haffen, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
Depression and Anxiety|January 31, 2020
Childhood maltreatment and clinical severity of treatment-resistant depression in a French cohort of outpatients (FACE-DR): One-year follow-upAntoine Yrondi, Bruno Aouizerate, Djamila Bennabi, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|April 29, 2023
Long-term benzodiazepine prescription in treatment-resistant depression: A national FACE-TRD prospective studyGuillaume Fond, Mélanie Faugere, Laurent Boyer, et al.
BMJ Open|July 28, 2022
Impact of a phone call with a medical student/general practitioner team on morbidity of chronic patients during the first French COVID-19 lockdown (COVIQuest): a cluster randomised trialClarisse Dibao-Dina, Julie Léger, Isabelle Ettori-Ajasse, et al.
Frontiers in Psychiatry|December 12, 2017
Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental)Antoine Yrondi, Djamila Bennabi, Emmanuel Haffen, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
Pageof 21